|
Biomarker testing patterns and use of targeted therapy in Medicare Fee-for-Service (FFS) beneficiaries newly diagnosed with metastatic non-small cell lung cancer (mNSCLC). |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Amgen |
|
|
|
Stock and Other Ownership Interests - Amgen |
Travel, Accommodations, Expenses - Amgen |
|
|
|
Stock and Other Ownership Interests - Amgen |
|
|
Employment - Amgen; Cancer Genetics |
Travel, Accommodations, Expenses - Amgen; Cancer Genetics |
|
|
Employment - Lilly; Lilly |
Consulting or Advisory Role - Avalere Health; Avalere Health (Inst) |
|
|
Consulting or Advisory Role - Amgen; Amgen (Inst) |
|
|
Consulting or Advisory Role - Amgen (Inst) |
|
|
Consulting or Advisory Role - Amgen (Inst) |
|
|
Consulting or Advisory Role - Amgen (Inst) |
|
|
Employment - Amgen; Amgen |
Stock and Other Ownership Interests - Amgen; Amgen Foundation; Merck; Merck |